Urispas

Suprapubic pain, Urethritis, Dysuria + 17 more

Treatment

10 FDA approvals

20 Active Studies for Urispas

What is Urispas

Flavoxate

The Generic name of this drug

Treatment Summary

Dicyclomine is a drug used to treat urinary and abdominal spasms. It works by numbing the area and blocking a certain type of nerve receptor that causes the spasms. It is unclear how effective this drug is and how exactly it works.

Urispas

is the brand name

image of different drug pills on a surface

Urispas Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Urispas

Flavoxate

1970

10

Approved as Treatment by the FDA

Flavoxate, otherwise known as Urispas, is approved by the FDA for 10 uses including urethrocystitis and Urinary Tract Infection (UTI) .

urethrocystitis

Urinary Tract Infection (UTI)

Urethritis

Urethrotrigonitis

Prostatitis

Prostatitis

Urethritis

Urethritis

Urethritis

Urinary Tract Infections

Effectiveness

How Urispas Affects Patients

Flavoxate is a drug used to treat bladder and urinary issues, such as incontinence, frequent urination, and urgency. It works by blocking a certain type of receptor (muscarinic) that helps control bladder muscle contractions and the production of saliva.

How Urispas works in the body

Flavoxate is a drug that works by blocking signals sent by nerves that control bladder contractions. This reduces muscle tension in the bladder and leads to fewer trips to the bathroom, fewer episodes of urge incontinence, less urgency and improved bladder control.

When to interrupt dosage

The recommended dosage of Urispas is contingent upon the identified condition, such as Menstrual Distress (Dysmenorrhea), urethrocystitis and Urinary Tract Infection. The measure of dosage shifts, in accordance with the method of delivery (e.g. Oral or Tablet, film coated - Oral) featured in the table beneath.

Condition

Dosage

Administration

cystalgia

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Pelvic Pain

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urinary Tract Infection (UTI)

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Catheterization

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Neurogenic Urinary Bladder

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Uterine dyskinesia

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urethritis

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Suprapubic pain

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urethritis

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Nocturia

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Kidney Stones

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urinary Tract Infections

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Dysmenorrhea

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urethritis

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urinary Incontinence

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Prostatitis

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Cystoscopy

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Cerebellar Diseases

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Urinary Urgency

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Dysuria

, 100.0 mg, 200.0 mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Warnings

Urispas is contraindicated in eight cases, and should not be amalgamated with the conditions delineated in the following table.

Urispas Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Ileus

Do Not Combine

Pyloric Stenosis

Do Not Combine

obstructive uropathies of the lower urinary tract

Do Not Combine

Gastrointestinal Hemorrhage

Do Not Combine

Intestinal Obstruction

Do Not Combine

Duodenal Obstruction

Do Not Combine

Esophageal Achalasia

Do Not Combine

There are 20 known major drug interactions with Urispas.

Common Urispas Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Flavoxate is combined with Aclidinium.

Cimetropium

Major

The risk or severity of adverse effects can be increased when Flavoxate is combined with Cimetropium.

Eluxadoline

Major

The risk or severity of constipation can be increased when Flavoxate is combined with Eluxadoline.

Glycopyrronium

Major

The risk or severity of adverse effects can be increased when Flavoxate is combined with Glycopyrronium.

Ipratropium

Major

The risk or severity of adverse effects can be increased when Flavoxate is combined with Ipratropium.

Urispas Toxicity & Overdose Risk

The amount of flavoxate HCl that is toxic to rats is 4273 mg/kg, and 1837 mg/kg for mice. Signs of an overdose include seizures, decreased sweating, red and warm skin, dry mouth, elevated body temperature, hallucinations, rapid heart rate and high blood pressure, and mental confusion.

image of a doctor in a lab doing drug, clinical research

Urispas Novel Uses: Which Conditions Have a Clinical Trial Featuring Urispas?

126 active clinical trials are assessing the efficacy of Urispas in providing relief from Urinary Incontinence, Cerebellar Diseases and Nocturia.

Condition

Clinical Trials

Trial Phases

Nocturia

7 Actively Recruiting

Not Applicable, Phase 4

Kidney Stones

34 Actively Recruiting

Early Phase 1, Not Applicable, Phase 2, Phase 1

Dysuria

0 Actively Recruiting

Urinary Tract Infection (UTI)

0 Actively Recruiting

Neurogenic Urinary Bladder

10 Actively Recruiting

Phase 3, Early Phase 1, Phase 2, Not Applicable, Phase 4, Phase 1

Catheterization

1 Actively Recruiting

Not Applicable

Uterine dyskinesia

0 Actively Recruiting

Dysmenorrhea

0 Actively Recruiting

Urinary Tract Infections

15 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1, Phase 3

Urethritis

1 Actively Recruiting

Phase 2

Urethritis

0 Actively Recruiting

Cystoscopy

0 Actively Recruiting

Urinary Urgency

2 Actively Recruiting

Not Applicable

Urinary Incontinence

2 Actively Recruiting

Phase 4, Not Applicable

Suprapubic pain

0 Actively Recruiting

Prostatitis

0 Actively Recruiting

cystalgia

0 Actively Recruiting

Pelvic Pain

14 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3

Urethritis

0 Actively Recruiting

Cerebellar Diseases

2 Actively Recruiting

Not Applicable

Urispas Reviews: What are patients saying about Urispas?

5

Patient Review

1/3/2022

Urispas for Urination During the Night

Since I was a baby, I've suffered from water infections. On a trip to India, I went to the doctor again for another infection. He took a urine sample and it tested positive for antibiotics. He prescribed me Urispas and, for three years now, I haven't had a single infection. They've changed my life--I'm 100% better.

5

Patient Review

9/2/2021

Urispas for Urinary Tract Irritation

This has been a total game-changer for me. I was given this while I was in India and it really helped me out of a tough spot. I had been struggling with what I later found out were recurring UTIs, and the antibiotics just weren't cutting it anymore. This treatment allowed me to go week after week without any pain or discomfort, and I'm so grateful for that.

5

Patient Review

5/24/2010

Urispas for Difficult or Painful Urination

This medication has been such a relief! I've suffered from bladder infections my whole life, and this is the first time I've found something that actually helps. The only downside is that if I take it too close together or on an empty stomach, I get a little nauseous.

3.3

Patient Review

6/22/2021

Urispas for Urinary Tract Irritation

This medication only provides temporary relief while it is active in your system. I was recommended this by a pharmacist when I told her about my UTI. The mornings are still the hardest, but once the medication kicks in I can finally empty my bladder. Unfortunately, even after finishing the dosage, the UTI symptoms persist.

2.7

Patient Review

7/14/2013

Urispas for Urination During the Night

I have interstitial cystitis and could not afford the other medication, Uribel. So, I decided to give this a try instead. Unfortunately, I felt very shaky and drowsy after taking it. Will not take this again!

2.3

Patient Review

4/7/2014

Urispas for Frequent Urination

I've been taking the medication as prescribed, but I haven't noticed any difference in my frequent urination.

1

Patient Review

8/23/2022

Urispas for Frequent Urination

I took antibiotics and probiotics to fight an infection, then I started taking urispas. Unfortunately, even after six days of use, there was no change.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about urispas

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will Urispas help for bladder infection?

"Urispas is not a treatment for bladder infections. Those must be treated with antibiotics. Urispas can also be used for other purposes not mentioned in this medication guide."

Answered by AI

Is Urispas antibiotic?

"Urispas is not a cure for infections, but is available in generic form."

Answered by AI

What is Urispas tablets used for?

"The drug Urispas contains an active ingredient that inhibits muscle contractions in the urinary tract. This effect can help to relieve pain caused by inflammation in the bladder, prostate gland, or urethra. Urispas is typically used to treat muscle spasms that occur in these areas."

Answered by AI

Is Urispas harmful?

"The following side effects may occur: nausea, vomiting, dry mouth, headache, drowsiness, dizziness, blurred vision, and nervousness. If you experience any of these side effects, tell your doctor or pharmacist."

Answered by AI

Clinical Trials for Urispas

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Have you considered Urispas clinical trials?

We made a collection of clinical trials featuring Urispas, we think they might fit your search criteria.
Go to Trials
Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Personalized Exercise for Chronic Pelvic Pain

18 - 55
Female
New York, NY

WorkoutCPP is a pilot study evaluating the feasibility of a personalized exercise recommendation system for individuals with chronic pelvic pain disorders (CPPDs). The study uses reinforcement learning (RL), a type of artificial intelligence that adapts recommendations over time based on each participant's reported pain levels, symptom burden, and exercise compliance. Participants receive daily exercise recommendations that alternate between standard, non-personalized guidance and personalized, RL-generated recommendations across four 2-week phases, allowing within-person comparison of outcomes under each condition. The primary hypothesis is that an RL-based adaptive recommendation system is feasible to deliver in a CPPD population.

Recruiting
Has No Placebo

Icahn School of Medicine at Mount Sinai

Ipek Ensari, PhD

Image of Sault Area Hospital in Sault Ste. Marie, Canada.

Mini-Flexible Ureteroscopy for Kidney Stones

18+
All Sexes
Sault Ste. Marie, Canada

This prospective, randomized, single-blinded, non-inferiority clinical trial will compare the clinical outcomes and cost-effectiveness of two mini-flexible ureteroscopes (6.3Fr and 7.5Fr) used during flexible ureteroscopy for the treatment of renal stones. Adult patients with renal stones up to 15 mm who are scheduled to undergo flexible ureteroscopy will be randomly assigned to one of the two study groups. The primary objectives are to compare stone-free rates and the ability to achieve primary renal access without preoperative ureteral stenting. Secondary outcomes include operative time, fluoroscopy use, ureteral trauma, postoperative stenting, pain, complications, emergency department visits, need for additional procedures, hospital stay, and cost-effectiveness. The results of this study are expected to provide high-quality evidence to guide the selection of mini-flexible ureteroscopes and improve the quality, safety, and value of surgical care for patients with kidney stones.

Waitlist Available
Has No Placebo

Sault Area Hospital

Yasser A Noureldin, MD, PhD

Image of MedStar National Rehabilitation Hospital in Washington D.C., United States.

Rapid UTI Diagnostics for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

Patients who seek care through MedStar National Rehab Hospital's clinic believing they have a UTI will be enrolled in this trial. They will be pre-screened after consent according to a standard-of-care clinical symptom measure called the USQNB. If determined by this measure to be at high or moderate likelihood of having a UTI, they will be assigned to the presumed UTI arm and instructed to come to the clinic to provide a urine sample and undergo standard diagnostic testing to determine if a UTI is present. Those not assigned to the presumed UTI arm at this phase are assigned to the presumed no UTI arm and do not present to the clinic. These tests include a repeated questionnaire about the UTI symptoms they are experiencing and collection of a urine sample from a freshly changed indwelling catheter for standard clinical urinalysis testing and culture. Based upon the clinical guideline-informed results of these standard clinical tests, patients will be assigned into one of two potential arms (suspected UTI or suspected non-UTI) based on whether or not they are diagnosed with UTI at that visit. Arm 1 (presumed UTI) participants will have a second urine sample collected at the time of the visit from the used indwelling catheter bag in addition to the freshly changed catheter sample, and both will be divided into three portions: one for repeat clinical tests and culture, one for assessment using the experimental Jiddu device, and one to be stored for potential future studies. The study doctor will then determine antibiotic choice according to standard clinical decision making and record, but not prescribe, that choice. Once results are obtained from the samples sent for experimental analysis, the study doctor will use those results in addition to their best clinical judgement and all standard available clinical evidence to choose the antibiotic treatment. Arm 1 participants will then complete urine symptom surveys at day 3 and 7 during antibiotic use to determine effectiveness of antibiotics prescribed. In the event of standard urine culture results differing from the Jiddu-produced pooled AST values rescue antibiotic consisting of the antibiotic choice based on best clinical judgement using this newly available evidence will be used to ensure safety and this survey clock will restart and include a USQNB on day 10. Arm 2 participants will repeat the urinary symptoms questionnaire 3 and 7 days after their initial completion to see if their symptoms have changed and would allow them to qualify. If they remain unqualified at 7 days, they will be instructed to fill out another survey the next time they think they have a UTI. This process will repeat until they either qualify to become an Arm 1 participant or 6 months have passed since they first consented.

Waitlist Available
Has No Placebo

MedStar National Rehabilitation Hospital

Ana Valeria Aguirre Guemez, MD

Image of Albany Medical Center Hospital in Albany, United States.

Midline Catheter vs Peripheral IV for Difficult Venous Access

18+
All Sexes
Albany, NY

Obtaining intravenous (IV) access is one of the most common procedures performed in the emergency department (ED). IV access is necessary for many aspects of patient care, including blood tests, administration of medications and intravenous fluids, and diagnostic imaging. However, some patients have difficult intravenous access (DIVA), making it challenging to successfully place an IV catheter. Difficulty obtaining IV access can lead to delays in diagnosis and treatment, prolonged emergency department stays, multiple needle punctures, and increased patient discomfort. Several specialized IV devices are available for patients with DIVA. Two commonly used ultrasound-guided devices are long peripheral intravenous catheters and single-lumen midline catheters. Both devices are inserted into veins using ultrasound guidance, but they differ in catheter length and expected duration of use. Long peripheral IV catheters are commonly used in emergency departments but may fail relatively quickly. Midline catheters may remain functional for longer periods and may reduce the need for additional IV insertions during a patient's hospital stay. However, these devices have traditionally been inserted by specialized clinicians, such as members of vascular access teams, rather than by bedside emergency department nurses, who perform most vascular access procedures in many emergency departments. The purpose of this study is to compare ultrasound-guided single-lumen midline catheters with ultrasound-guided long peripheral IV catheters when both procedures are performed by specially trained bedside emergency department nurses. The study will evaluate whether midline catheters can be inserted as successfully and as safely as long peripheral IV catheters in adult emergency department patients with difficult intravenous access. Participants will be randomly assigned to receive either an ultrasound-guided single-lumen midline catheter or an ultrasound-guided long peripheral IV catheter. Researchers will compare the two devices by measuring procedural success, catheter-related complications, catheter dwell time, completion of care using the original device, and patient satisfaction. The results of this study may help determine whether bedside emergency department nurses with training and experience in ultrasound-guided vascular access can successfully use single-lumen midline catheters in routine clinical practice. The study will also evaluate which vascular access device provides the best balance of safety, reliability, and patient experience for emergency department patients with difficult intravenous access. This information may help guide future recommendations for vascular access device selection in the emergency department.

Recruiting
Has No Placebo

Albany Medical Center Hospital

Becton, Dickinson and Company

Have you considered Urispas clinical trials?

We made a collection of clinical trials featuring Urispas, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Educational Videos for Pre-operative Anxiety

18+
Female
Farmington, CT

The goal of this clinical trial is to learn if educational videos can reduce pre-operative anxiety in patients undergoing minimally invasive gynecologic surgery. The main question it aims to answer are: do patient education videos decrease preoperative anxiety? do patient education videos increase patient preparedness for surgery? Researchers will compare the group who watched the videos preoperatively to the group who only underwent the usual counseling at the preoperative visit to see if the results of a survey that measures anxiety and preparedness differ. Participants will be randomly assigned to one of two groups: one group that will be asked to watch the educational videos and one group that will not. All participants will attend their pre-operative appointment as usual and complete a survey afterwards.

Waitlist Available
Has No Placebo

UConn Health

Have you considered Urispas clinical trials?

We made a collection of clinical trials featuring Urispas, we think they might fit your search criteria.
Go to Trials